Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A [[R]]recombinant vector system comprising at least one copy of a first nucleic acid encoding the antigen-binding site of the heavy chain of an antibody, said first nucleic acid comprising
   a nucleotide sequence encoding SEQ ID NO:24,
   a nucleotide sequence encoding SEQ ID NO:25, and
   a nucleotide sequence encoding SEQ ID NO:26, ~~the CDR3 region (designated H3), or/and encoding the CDR2 region (designated H2), or/and encoding the CDR1 region (designated H1), as shown in Figure 1 or/and Figure 6,~~ and
   at least one copy of a second nucleic acid encoding the antigen-binding site of the light chain of an antibody, said second nucleic acid comprising
   a nucleotide sequence encoding SEQ ID NO:27,
   a nucleotide sequence encoding SEQ ID NO:28, and
   a nucleotide sequence encoding SEQ ID NO:29,~~the CDR3 region (designated L3), or/and encoding the CDR2 region (designated L2), or/and encoding the CDR1 region (designated L1), as shown in Figure 1 or/and Figure 6,~~
   wherein the first and second nucleic acids encoding the antigen-binding site of the heavy chain and of the light chain have separate expression control sequences.

2. (Currently amended) The [[R]]recombinant vector system according to claim 1 comprising a first recombinant vector comprising at least one copy of a nucleic acid encoding the antigen-binding site of the heavy chain and a second recombinant vector comprising at least one copy of a nucleic acid encoding the antigen-binding site of the light chain.

3. (Currently amended) The [[R]]recombinant vector system according to claim 1 wherein at least one copy of the nucleic acid encoding the antigen-binding site of the heavy chain and of the light chain are located on the same recombinant vector.

4. (Currently amended) A [[M]]method for the recombinant production of a polypeptide having an antigen-binding site comprising:

(a) providing a recombinant vector system according to claim 1,

(b) introducing the recombinant vector system into a suitable host cell,

(c) culturing the host cell under suitable conditions in a medium whereby an expression of the polypeptide takes place and

(d) obtaining the expressed product from the medium and/or the host cell.

5. (Previously Presented) The method of claim 4, wherein the host cell is a mammalian cell.

6. (Currently amended) The method of claim 4, wherein between steps (a) and (b) a modification of the vector system takes place wherein the modification ~~substantially~~ does not alter the amino acid sequence of the antigen-binding site of the polypeptide to be expressed.

7. (Previously Presented) The method of claim 4 further comprising preparing a diagnostic or therapeutic agent from the expressed product.

8. (Previously Presented) The method of claim 7, wherein the expressed product is coupled to a diagnostic marker.

9. (Previously Presented) The method of claim 7, wherein the expressed product is coupled to a cytotoxic agent.

10. (Previously Presented) The method of claim 4, wherein the expressed product is selected from antibodies and antibody fragments.

11. (New) The method of claim 8, wherein the diagnostic marker is a radioactive marker.